NASDAQ:CYTX Cytori Therapeutics (CYTX) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free CYTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.94▼$2.2550-Day Range$0.20▼$0.2152-Week Range$0.20▼$0.75Volume69,276 shsAverage Volume915,302 shsMarket Capitalization$44.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsTrendsStock AnalysisCompetitorsTrends Get Cytori Therapeutics alerts: Email Address Ad WealthPressThe only trade perfect for TSLA Tesla is one of the most envied companies in the world… The stock has averaged a 37% annual return over the last decade. In fact, it’s up 2,136% in that time. Yet many folks think they’re “too late” to tap into the power of TSLA… But one trading expert from Florida says there’s still a massive opportunity buried inside its shares… According to his research, this opportunity would’ve allowed everyday traders to target gains of 100% or more… in sx days or less It’s all thanks to something called The Perfect Tesla Trade.>> Click here to join Lance now and he’ll teach you how to execute the Perfect Tesla Trade inside yo About Cytori Therapeutics Stock (NASDAQ:CYTX)Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.Read More Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… CYTX Stock News HeadlinesFebruary 9, 2024 | investing.comCheckpoint Therapeutics Inc (CKPT)November 4, 2023 | morningstar.comSage Therapeutics Inc SAGESeptember 27, 2023 | thestreet.com5 Biotech Stocks Under $10 Blasting HigherOctober 16, 2022 | finance.yahoo.comWomen’s Health Therapeutics Market Research Report by Type, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19August 29, 2022 | thestreet.com8 Stocks Under $10 Ripping HigherSee More Headlines Receive CYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2019Today6/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryBiotechnology Current SymbolNASDAQ:CYTX CUSIP23283K10 CIK1095981 Webwww.cytori.com Phone858-458-0900FaxN/AEmployees37Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,630,000.00 Net Margins-242.60% Pretax MarginN/A Return on Equity-272.70% Return on Assets-56.23% Debt Debt-to-Equity Ratio0.39 Current Ratio0.46 Quick Ratio0.30 Sales & Book Value Annual Sales$3.67 million Price / Sales12.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book5.71Miscellaneous Outstanding Shares22,160,000Free FloatN/AMarket Cap$44.32 million OptionableNot Optionable Beta1.96 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMarc H. HedrickPresident, Chief Executive Officer & DirectorGary S. TitusChief Financial OfficerMark T. MarinoChief Medical Officer & Senior Vice PresidentJohn K. FraserChief ScientistRuss HavranekVP-Global Marketing & Business DevelopmentKey CompetitorsAchieve Life SciencesNASDAQ:ACHVRigel PharmaceuticalsNASDAQ:RIGLRegulus TherapeuticsNASDAQ:RGLSSangamo TherapeuticsNASDAQ:SGMOVerastemNASDAQ:VSTMView All Competitors CYTX Stock Analysis - Frequently Asked Questions How were Cytori Therapeutics' earnings last quarter? Cytori Therapeutics Inc (NASDAQ:CYTX) issued its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative trailing twelve-month return on equity of 272.70% and a negative net margin of 242.60%. When did Cytori Therapeutics' stock split? Cytori Therapeutics shares reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Cytori Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), Exelixis (EXEL), Athersys (ATHX), BCE (BCE), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX). This page (NASDAQ:CYTX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.